Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a slight increase in stock price and a mixed flow of funds on February 4, 2026 [1][2] - As of February 4, 2026, Tongce Medical's stock closed at 48.84 yuan, up 1.2%, with a turnover rate of 3.11% and a trading volume of 139,300 hands, amounting to a total transaction value of 675 million yuan [1] - The fund flow data shows a net outflow of 30.88 million yuan from main funds, accounting for 4.57% of the total transaction value, while retail investors saw a net inflow of 42.81 million yuan, representing 6.34% of the total transaction value [1] Group 2 - In the third quarter of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The company's third-quarter performance included a single-quarter main revenue of 842 million yuan, reflecting a 2.34% year-on-year increase, and a net profit of 192 million yuan, which is a 2.31% increase year-on-year [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while maintaining a gross profit margin of 41.69% [2]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a positive trend in both stock price and financial results [1][2] - As of February 3, 2026, Tongce Medical's stock closed at 48.26 yuan, reflecting a 2.25% increase with a trading volume of 170,400 hands and a total transaction amount of 818 million yuan [1] - In terms of capital flow on February 3, 2026, the net inflow of main funds was 44.53 million yuan, accounting for 5.44% of the total transaction amount, while retail investors experienced a net outflow of 2.59 million yuan, representing 0.32% of the total [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The third quarter of 2025 saw a single-quarter main revenue of 842 million yuan, reflecting a 2.34% year-on-year increase, with a net profit of 192 million yuan, up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, alongside a gross profit margin of 41.69% [2] Group 3 - Over the past 90 days, five institutions have provided ratings for Tongce Medical, with three giving a "buy" rating and two an "increase" rating, while the average target price set by institutions is 51.1 yuan [2]

Group 1 - The core point of the article is that Tongce Medical (600763) reported a total of 90,200 shareholders as of January 31, 2026 [1]

Core Viewpoint - The company, Tongce Medical, reported that as of January 31, 2026, the total number of shareholders is 90,200 households, emphasizing the importance of official disclosures for accurate information [1]. Group 1 - The total number of shareholders for Tongce Medical is 90,200 households as of January 31, 2026 [1]. - The company encourages investors to refer to official periodic reports for accurate shareholder information [1].

Group 1 - The core viewpoint of the news is that Tongce Medical's stock has increased by 5%, reaching a price of 48.30 yuan per share, with a trading volume of 481 million yuan and a turnover rate of 2.25%, resulting in a total market capitalization of 21.604 billion yuan [1] - Tongce Medical Co., Ltd. is located in Hangzhou, established on August 30, 1995, and listed on October 30, 1996. The company's main business involves medical service investment and dental medical services [1] - The revenue composition of Tongce Medical is as follows: medical services account for 92.84%, product sales 4.06%, construction engineering 2.72%, and others 0.38% [1] Group 2 - From the perspective of the top ten circulating shareholders of Tongce Medical, Huabao Fund holds a position in the top ten shareholders, with the Huabao CSI Medical ETF (512170) reducing its holdings by 1.5804 million shares in the third quarter, now holding 8.8854 million shares, which represents 1.99% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a latest scale of 25.263 billion yuan. Year-to-date return is 4.77%, ranking 2834 out of 5579 in its category; the one-year return is 14.49%, ranking 3655 out of 4285; and since inception, the return is 6.66% [2] - The fund manager of Huabao CSI Medical ETF is Hu Jie, who has a cumulative tenure of 13 years and 113 days, with the total asset scale of 101.358 billion yuan. The best fund return during his tenure is 162.35%, while the worst is -98.01% [2]

Core Viewpoint - Tongce Medical (600763) has shown a positive performance with a closing price of 47.49 yuan, reflecting a 5.14% increase as of January 29, 2026, with significant trading volume and turnover [1] Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3] - The net profit attributable to shareholders reached 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, increasing by 3.09% [3] - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, a 2.34% year-on-year increase, and a net profit of 192 million yuan, up 2.31% [3] - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, resulting in a gross profit margin of 41.69% [3] Market Activity - On January 29, 2026, the net inflow of main funds was 117 million yuan, accounting for 12.09% of the total turnover, while retail investors experienced a net outflow of approximately 57.90 million yuan [1] - The financing data indicates a financing buy of 67.31 million yuan and a financing repayment of 80.66 million yuan, resulting in a net repayment of 13.34 million yuan [2] - The stock has received ratings from four institutions in the last 90 days, with two buy ratings and two hold ratings, and the average target price set at 51.1 yuan [3]

Group 1 - The core index of Zhongzheng Medical (399989) closed at 7194.8 points, with an increase of 1.48% on January 29, and a total transaction volume of 32.905 billion yuan, resulting in a turnover rate of 3.17% [1] - Among the constituent stocks of the index, 32 stocks rose, with Tongce Medical leading the gains at 5.14%, while 18 stocks fell, with Haoyuan Pharmaceutical leading the declines at 5.68% [1] Group 2 - The net inflow of main funds into the constituent stocks of Zhongzheng Medical (399989) was 1.497 billion yuan, while the net outflow of speculative funds was 232 million yuan, and the net outflow of retail funds was 1.249 billion yuan [2] - Detailed fund flow information for the constituent stocks is available in the accompanying table [2]

Core Insights - The medical services sector experienced a rise of 1.61% on January 29, with Tongce Medical leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Services Sector Performance - Tongce Medical (600763) closed at 47.49, with a gain of 5.14%, and a trading volume of 206,500 shares, amounting to a transaction value of 9.65 billion [1] - Other notable performers included: - Digital Human (920670) at 20.26, up 3.90%, with a transaction value of 2.08 billion [1] - Meinian Health (002044) at 7.28, up 3.70%, with a transaction value of 24.68 billion [1] - Tiger Medical (300347) at 58.91, up 3.51%, with a transaction value of 7.82 billion [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.146 billion from institutional investors, while retail investors experienced a net outflow of 1.043 billion [2][3] - Key stocks with significant capital flow included: - WuXi AppTec (603259) with a net inflow of 306 million, representing 5.87% of total capital [3] - Aier Eye Hospital (300015) with a net inflow of 228 million, representing 15.83% of total capital [3] - Meinian Health (002044) with a net inflow of 163 million, representing 6.60% of total capital [3]

Group 1 - The core viewpoint of the news is that Tongce Medical's stock price increased by 5.11% to 47.48 CNY per share, with a trading volume of 836 million CNY and a turnover rate of 4.01%, resulting in a total market capitalization of 21.237 billion CNY [1] - Tongce Medical Co., Ltd. is located in Hangzhou, established on August 30, 1995, and listed on October 30, 1996. The company primarily engages in medical service investment and dental medical services [1] - The revenue composition of Tongce Medical is as follows: medical services account for 92.84%, product sales 4.06%, construction engineering 2.72%, and others 0.38% [1] Group 2 - Among the top circulating shareholders of Tongce Medical, a fund under Southern Fund holds a significant position. The Southern CSI 500 ETF (510500) reduced its holdings by 106,700 shares in the third quarter, now holding 4.5641 million shares, which is 1.02% of the circulating shares [2] - The Southern CSI 500 ETF (510500) was established on February 6, 2013, with a latest scale of 144.69 billion CNY. Year-to-date returns are 15.26%, ranking 552 out of 5,551 in its category; over the past year, returns are 56.56%, ranking 1,089 out of 4,285; and since inception, returns are 190.06% [2] - The fund manager of Southern CSI 500 ETF (510500) is Luo Wenjie, who has a cumulative tenure of 12 years and 286 days, with total fund assets of 171.358 billion CNY. The best fund return during his tenure is 192.55%, while the worst is -47.6% [2]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a decline in stock price and mixed capital flow trends [1][2] - As of January 28, 2026, Tongce Medical's stock closed at 45.17 yuan, down 2.08%, with a turnover rate of 1.96% and a trading volume of 87,700 hands, resulting in a transaction amount of 398 million yuan [1] - In terms of capital flow on January 28, 2026, the net outflow of main funds was 41.39 million yuan, accounting for 10.39% of the total transaction amount, while retail investors saw a net inflow of 69.01 million yuan, representing 17.33% of the total transaction amount [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The third quarter of 2025 showed a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, with a net profit of 192 million yuan, also up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, investment income of 41.22 million yuan, financial expenses of 31.93 million yuan, and a gross profit margin of 41.69% [2] Group 3 - Over the past 90 days, five institutions have provided ratings for Tongce Medical, with three buy ratings and two hold ratings, and the average target price set by institutions is 52.15 yuan [2]